ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce ...
Pipeline
ImmuPharma PLC is a biopharmaceutical company developing novel peptide therapeutics.
Our pipeline is focused on two core therapeutic areas; autoimmunity & inflammation and anti-infectives.
*Phase 2/3 adaptive trial becomes a pivotal trial for filing
Our core therapeutic areas
The P140 platform
LUPUZORTM for Lupus
P140 for CIDP
BioAMB
for systemic fungal infections
BioCIN
for severe bacterial infections
Key progress
Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce ...
Phase 2/3 adaptive study design for Lupus study agreed with Avion
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to ...